Skip to main content

Table 4 Antibody titers and protection against SG-MCMV challenge in mice immunized with various doses of FI-MCMV with or without adjuvant by i.m. injection a

From: An adjuvanted inactivated murine cytomegalovirus (MCMV) vaccine induces potent and long-term protective immunity against a lethal challenge with virulent MCMV

Immunogen

FI-MCMV

ELISA titer (2n) of IgG antibodyb

Protection against SG-MCMV challenge

Dosage (μg)

Immunization once

Immunization twice

Spleen virus titers (log10PFU/ml)

Survival mice/tested mice

Adjuvant-free

0.25

3.67 ± 1.15

5.33 ± 0.58

5.27 ± 0.19

0/6

+ Chitosan

 

5.00 ± 1.00

9.67 ± 1.15c

5.08 ± 0.13

0/6

+ Alum

 

6.33 ± 1.53c

11.33 ± 1.15c

5.14 ± 0.11

0/6

+ MF59

 

7.33 ± 0.58c

12.33 ± 1.53c

4.58 ± 0.36c,e

2/6

Adjuvant-free

1

4.67 ± 1.15

10.00 ± 1.73

5.13 ± 0.29

0/6

+ Chitosan

 

6.33 ± 0.58

12.00 ± 1.00c

4.64 ± 0.50e

2/6

+ Alum

 

7.33 ± 0.58c

12.33 ± 1.15c

4.78 ± 0.15e

1/6

+ MF59

 

10.67 ± 1.15c,d

15.00 ± 1.00c,d

3.51 ± 0.49c,d,e

5/6e

Adjuvant-free

4

7.67 ± 0.58

11.67 ± 1.52

4.41 ± 0.48e

3/6

+ Chitosan

 

10.00 ± 1.73c

13.67 ± 0.58c

4.02 ± 0.51e

5/6e

+ Alum

 

10.33 ± 0.58c

14.00 ± 1.00c

3.80 ± 0.11c,e

6/6e

+ MF59

 

11.67 ± 0.58c

16.33 ± 0.58c,d

2.56 ± 0.77c,d,e

6/6e

Chitosan only

-

Undetected

Undetected

5.87 ± 0.17

0/6

Alum only

 

Undetected

Undetected

5.68 ± 0.27

0/6

MF59 only

 

Undetected

Undetected

5.62 ± 0.38

0/6

Mock

 

Undetected

Undetected

5.73 ± 0.34

0/6

PBS

 

-

-

5.91 ± 0.39

0/6

  1. aThe mice were immunized twice (3 weeks apart) with various doses of vaccine (0.25, 1, or 4 μg) with or without adjuvant (MF59, alum, or chitosan) by i.m. injection. Serum samples from immunized mice were obtained 3 weeks after the first and second immunization, respectively. Three weeks after immunization, all the mice were challenged with a lethal dose of SG-MCMV. Spleen virus titers 5 days after challenge and survival rates of mice 21 days post-infection were determined. Results are expressed as means ± SD of tested mice in each group.
  2. bSerum samples were diluted by two-fold serial dilutions and “n” represents the dilution factor.
  3. cSignificant difference (p < 0.05), compared with the corresponding adjuvant-free subjects.
  4. dSignificant difference (p < 0.05), compared with the corresponding alum adjuvant subjects.
  5. eSignificant difference (p < 0.05), compared with corresponding control subjects.